Pal SK - Search Results

1

Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices.

Salgia NJ, Philip EJ, Ziari M, Yap K, Pal SK. Salgia NJ, et al. Among authors: pal sk. J Clin Med. 2020 May 17;9(5):1508. doi: 10.3390/jcm9051508. J Clin Med. 2020. PMID: 32429554 Free PMC article.

2

Renal cell carcinoma therapy in 2010: many options with little comparative data.

Pal SK, Figlin RA. Pal SK, et al. Clin Adv Hematol Oncol. 2010 Mar;8(3):191-200. Clin Adv Hematol Oncol. 2010. PMID: 20400934 Review.

3

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.

Pal SK, Figlin RA. Pal SK, et al. Clin Med Insights Oncol. 2010 Jun 9;4:43-53. doi: 10.4137/cmo.s1590. Clin Med Insights Oncol. 2010. PMID: 20711245 Free PMC article.

4

Quality of life in patients with metastatic renal cell carcinoma: assessment of long-term survivors.

Carmichael C, Yuh BE, Sun V, Lau C, Hsu J, Saikia J, Liu X, Wilson T, Ferrell B, Pal SK. Carmichael C, et al. Among authors: pal sk. Clin Genitourin Cancer. 2013 Jun;11(2):149-54. doi: 10.1016/j.clgc.2012.09.006. Epub 2012 Oct 9. Clin Genitourin Cancer. 2013. PMID: 23058499 Free PMC article. Clinical Trial.

5

Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma.

Pal SK, Vogelzang NJ. Pal SK, et al. Clin Adv Hematol Oncol. 2013 Mar;11(3):146-55. Clin Adv Hematol Oncol. 2013. PMID: 23598982 Review.

6

Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.

Pal SK, Hu A, Chang M, Figlin RA. Pal SK, et al. Clin Adv Hematol Oncol. 2014 Feb;12(2):90-9. Clin Adv Hematol Oncol. 2014. PMID: 24892254 Review.

7

Characterizing the outcomes of metastatic papillary renal cell carcinoma.

Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, Rha SY, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishampayan UN, Wood LA, Simpson R, De Velasco G, Choueiri TK, Heng DYC. Connor Wells J, et al. Among authors: pal sk. Cancer Med. 2017 May;6(5):902-909. doi: 10.1002/cam4.1048. Epub 2017 Apr 16. Cancer Med. 2017. PMID: 28414866 Free PMC article.

8

Biopsychosocial distress and clinical outcome in metastatic renal cell carcinoma.

Bergerot CD, Clark KL, Ashing KT, Bergerot PG, Obenchain R, Dizman N, Hsu J, Philip E, Loscalzo M, Pal SK. Bergerot CD, et al. Among authors: pal sk. Palliat Support Care. 2019 Jun;17(3):353-355. doi: 10.1017/S1478951518000342. Epub 2018 Jun 18. Palliat Support Care. 2019. PMID: 29911518

9

Adjuvant treatment in renal cell carcinoma.

Dizman N, Adashek JJ, Hsu J, Bergerot PG, Bergerot CD, Pal SK. Dizman N, et al. Among authors: pal sk. Clin Adv Hematol Oncol. 2018 Aug;16(8):555-563. Clin Adv Hematol Oncol. 2018. PMID: 30148828 Review.

10

Assessment of distress and quality of life in rare cancers.

Bergerot CD, Bergerot PG, Philip EJ, De Domenico EBL, Manhaes MFM, Pedras RN, Salgia MM, Dizman N, Ashing KT, Li M, Dale W, Pal SK. Bergerot CD, et al. Among authors: pal sk. Psychooncology. 2018 Dec;27(12):2740-2746. doi: 10.1002/pon.4873. Epub 2018 Sep 25. Psychooncology. 2018. PMID: 30171792

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,102 results

Search Page